Needs and new policies for medicines for children: The FDA, United States incentives, and international doings

被引:1
作者
Botstein, P [1 ]
机构
[1] Botstein Associates, Bethesda, MD 20816 USA
来源
DRUG INFORMATION JOURNAL | 2000年 / 34卷 / 01期
关键词
pediatric; FDA; international; clinical study;
D O I
10.1177/009286150003400127
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Most prescription medicines in the United Stares and in other countries are not labeled with sufficient information for sensible use in the pediatric population, even though many drugs are widely used for disorders present in bath children and adults. The Food and Drug Administration (FDA) has launched initiatives to get pediatric use information into labeling of medicines in the United States: a 1998 regulation requiring that drugs be studied in the pediatric population; marketing exclusivity for obtaining pediatric data; and a 1994 labeling regulation allowing use of adult safety and effectiveness data as a basis for pediatric use of drugs. Harmonization, of international pediatric drug policies and regulations could increase the global availability of drugs labeled for pediatric use. The goal is greater availability worldwide of information on pediatric dosing, pharmacokinetics, and avoidance of safety problems.
引用
收藏
页码:203 / 205
页数:3
相关论文
共 2 条
[1]  
[Anonymous], 1994, FED REGISTER, V16, P64240
[2]  
Federal Register, 1998, FED REGISTER, V63, P66632